目的：观察Beclin1在非小细胞肺癌（non-small cell lung cancer, NSCLC）中的表达情况，探讨其与EGFR突变的相关性。方法：分别采用DNA直接测序法、免疫组化法检测42例NSCLC患者EGFR突变情况及Beclin1表达情况，分析二者之间关系及临床意义。结果：与癌旁组织比较，NSCLC组织中Beclin1高表达（71.4% vs 30.9%, P<0.01），Beclin1的表达与吸烟史、病理类型有关（P=0.005，P=0.025）。EGFR突变14例，其中高表达Beclin1 11例，低表达Beclin1 2例，突变率为57.9%( 11/19) vs 16.7%（2/12), Beclin1的表达与EGFR突变具有显著正相关性（r=0.416, P=0.009）。结论： NSCLC患者EGFR突变与 Beclin1的表达具有正相关性，Beclin1表达情况在一定程度上有助于判断NSCLC的EGFR突变状况，可能为判断EGFR突变提供有意义的线索。

Objective:To observe the expression of Beclin1 in the tissues of non-small cell lung cancer (NSCLC) and to investigate its correlation with EGFR mutation. Methods: Immunohistochemistry and DNA sequencing were used to detect the expression of Beclin1 and EGFR mutation in 42 patients with NSCLC, respectively. The clinical significance and their correlations were analyzed. Results: he expression levels of Beclin1 were significantly higher in NSCLC tissues than that in the para-carcinoma normal tissues（71.4% vs 30.9%, P<0.01). The expression of Beclin1 in NSCLC was associated with smoking history and histological type (P=0.005, P=0.025). There were 14 cases with EGFR mutation, among which 11 cases expressed high level of Beclin1 and 2 cases expressed low level of Beclin1, with a mutation rate of 57.9% (11/19) vs 16.7% (2/12). EGFR mutation and the expression of Beclin1 had a significant correlation (r=0416, P=0009).Conclusion: EGFR mutation in NSCLC patients was positively correlated with Beclin1 expression. Beclin1 could help to determine EGFR mutation in NSCLC patients at certain level, and could provide a meaningful evidence to determine EGFR mutation.

上海市科委计划项目（No.15411960400）